Hôtel Dieu Saint Jacques
Toulouse, France

March 12, 2025

CONFIDENTIAL
DO NOT DISTRIBUTE

TASK FORCE ICFSR & GEROSCIENCE

PRE-CLINICAL AND CLINICAL TRIALS

Luigi Ferrucci (USA)

Roger Fielding (USA)

John Newman (USA)

Bruno Vellas (France)

TASK FORCE ICFSR & GEROSCIENCE PRE-CLINICAL AND CLINICAL TRIALS

March 12, 2025 (Toulouse - France)

PROGRAM

8:15 a.m. **Welcome coffee and networking**

8:45 – 9:00 a.m. Introduction: *Luigi Ferrucci*[1], *Roger Fielding*[2], *Bruno Vellas*[3], *John Newman*[4]
1. National Institute on Aging *(Baltimore, MD – USA)*; 2. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University *(Boston, MA – USA);* 3. IHU HealthAge *(Toulouse, France)*; 4. Buck Institute *(Novato, CA – USA)*

9:00 – 9:15 a.m. Geroscience pre-clinical and clinical trials where we are and where we must go
Luigi Ferrucci
National Institute on Aging *(Baltimore, MD – USA)*

9:15 – 9:30 a.m. Reconciling the harmful versus beneficial roles of cellular senescence and the role of senolytics in multimorbidity
George Kuchel
Uconn Health *(Farmington, CT – USA)*

9:30 – 9:45 a.m. Blood-Based Protein Biomarkers of Longevity – A Path to Implementation in Clinical Trials
Amos Baruch
Calico Life Sciences *(South San Francisco, CA – USA)*

9:45 – 10:00 a.m. **Discussion**

Randomized Controlled Trials in Geroscience

Co-Chairs: *Felipe Sierra*[1], *George Kuchel*[2]
1. Hevolution Foundation *(Boston, MA – USA); 2*. Uconn Health *(Farmington, CT – USA)*

10:00 – 10:15 a.m. RCTs of NAD augmentation
Shalender Bhasin
Brigham and Women's Hospital *(Boston, MA – USA)*

10:15 – 10:30 a.m. Launching TAKEOFF: Pilot data on a ketone ester informing a multicenter RCT
John Newman
Buck Institute *(Novato, CA – USA)*

10.30 – 10.45 a.m. Moving from basic research to RCT
Nathan LeBrasseur
Mayo Clinic *(Rochester, Minnesota – USA)*

10:45 – 11:00 a.m. **Discussion**

Pre-Clinical and Clinical Trials in Geroscience: Short communications

Co-Chairs: *Jean-Yves Reginster*[1], *Bruno Vellas*[2]

1. College of Science, King Saud University *(Riyadh – Saudi Arabia)*; 2. IHU HealthAge *(Toulouse – France)*

11:00 – 11:10 a.m. Geroscience guided rapamycin clinical trials: Rationale and experimental design
Adam Konopka
University of Wisconsin-Madison *(Madison, WI – USA)*

11:10 – 11:20 a.m. Role of cell therapy in osteoarthritis
Ali Mobasheri[1], *Jean-Yves Reginster*[2]
1. Faculty of Medicine, University of Oulu *(Oulu – Finland)*
2. College of Science, King Saud University *(Riyadh – Saudi Arabia)*

11:20 – 11:30 a.m. Identifying and targeting pathological senescent articular cells to delay joint degeneration in age-related osteoarthritis
Jean-Marc Brondello
IRMB Montpellier University and INSERM UMR1183 *(Montpellier – France)*

11:30 – 11:40 a.m. Late-onset exercise training intervention promotes a healthy aging signature in skeletal muscle by improving mitochondrial health and functional status
Maria Carmen Gomez-Cabrera
University of Valencia, INCLIVA *(Valencia – Spain)*

11:40 – 11:50 a.m. Inorganic polyphosphate and dietary restriction: interactions between physiology and age-related pathology
Luca Tagliafico
University of Genoa and IRCCS Ospedale Policlinico San Martino *(Genoa – Italy)*

11:50 – 12:00 p.m. Leveraging Geroscience to Target Novel Mechanisms in Genitourinary Disease: The Prescription exercise for Older men with Urinary Disease (PROUD) Trial
Scott Bauer
University of California San Francisco *(San Francisco, CA – USA)*

12:00 – 12:15 p.m. Discussion

12.15 – 1.00 p.m. Lunch

Pre-Clinical and Clinical Trials in Geroscience: Short communications

Co-Chairs: *Roger Fielding*[1], *Yves Rolland*[2]

1. Tufts University *(Boston, MA – USA)*; 2. IHU HealthAge *(Toulouse – France)*

1:00 – 1:10 p.m. Sex dependent senotherapeutic effects is predicted by visceral adipose tissue response in aging and Alzheimer's models
Kevin Hascup
Southern Illinois University School of Medicine *(Springfield, IL – USA)*

1:10 – 1:20 p.m. ICOPE + Geroscience Proof of Concept Trial
Yves Rolland
IHU HealthAge *(Toulouse – France)*

1:20 – 1:30 p.m. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial
Heike Bischoff-Ferrari
University Department of Aging Medicine Felix Platter *(Basel – Switzerland)*

1:30 – 1:40 p.m. The effects of therapeutic plasma exchange (plasmapheresis) on age-related biomarkers: a double-blind, placebo-controlled clinical trials
Dobri Kiprov
Global Apheresis *(Mill Valley, CA – USA)*

1:40 – 1:50 p.m. General discussion

Pre-Clinical and Clinical Trials in Geroscience: Short communications

Co-Chairs: *John Newman*[1], *Philipe Barreto*[2]
1. Buck Institute *(Novato, CA – USA)*; 2. IHU HealthAge *(Toulouse – France)*

1:50 – 2:00 p.m. Mapping the responsiveness of 100+ epigenetic biomarkers Across 50+ anti-aging interventions in human clinical trials
Raghav Sehgal
Yale University *(New Haven, CT – USA)*

2:00 – 2:10 p.m. Omics aging biomarkers for clinical trials using the TranslAGE Knowledgebase
Albert Higgins-Chen
Yale University *(New Haven, CT – USA)*

2:10 – 2:20 p.m. Novel gerotherapeutic peptide PTC-2105 reverses the aging phenotype in naturally aged mice
Kevin Slawin
Eos Senolytix, Inc. *(Surfside, FL – USA)*

2:20 – 2:30 p.m. Context-dependent role of senescent cells, senescence heterogeneity, and the effect of senolytics
Raghavan Pillai Raju
Medical College of Georgia *(Augusta, GA – USA)*

2:30 – 2:40 p.m. Effect of a multifactorial weight loss intervention on HDL cholesterol efflux capacity and immunosenescence: A randomized controlled trial
Lidia Daimiel
Fundacion IMDEA Alimentacion *(Madrid – Spain)*

2:40 – 2:55 p.m. General discussion

3:00 p.m. ICFSR Conference Opening

SHORT PARTICIPANT PRESENTATIONS

ABIZANDA SOLER Pedro

Pedro Abizanda, MD, PhD. Head of the Geriatrics Department of the Complejo Hospitalario Universitario of Albacete since 2012. Specialist in Geriatric Medicine since1992.Physical Doctor (PhD) since 2000 (Medicine Faculty, Universidad Autónoma de Madrid). Master in research in 2011 (Universidad Autónoma de Barcelona). Full Professor of Geriatric Medicine, Medicine Faculty, Universidad de Castilla-La Mancha (UCLM). Coordinator of Geriatric Medicine teaching at the Medicine Faculty of Albacete (UCLM) since 2002. President of the Ethics Review Committee from Albacete since 2010. Head of the research group for translational research on aging in Albacete (GAITE). Member of Spanish Biomedical Research Network of Frailty and Healthy Aging (CIBERFES). Principal Investigator in 25 randomized clinical trials, and in 13 national and international competitive projects (AES, FIS, FISCAM, INSERSO, EIT-Health, H2020). Two registered patents. Identificator ORCID 0000-0002-4707-2963. Scopus author ID 55911178000: 95 Documents with 526 coauthors and 2125 citations in 1856 documents. h-index 26. More than 20 chapters in books, and 5 complete books as editor, including the «Geriatric Medicine Spanish Textbook» (Elsevier, first ed in 2014, second ed in 2020). More than 120 invited conferences in national and international congresses. More than 350 communications and posters at congresses. Director of 19 doctoral theses. Reviewer of more than 20 international journals. Member of the Joint Action in Frailty from DG-Santè 2017-2020, and of the Group of the Spanish Health Ministery «Prevention of Frailty and Falls». Main research topics of interest: Frailty, Sarcopenia, Clinical Trials in older adults, Falls, Dementia, Physical exercise, and Polypharmacy.

AERSSENS Jeroen

Jeroen Aerssens, PhD, is the Chief Development Officer at Rejuvenate Biomed, where he leads the clinical research and development activities. Rejuvenate Biomed is a clinical-stage biotech dedicated to the development of therapeutics that alter the course of age-related diseases. Jeroen builds on more than 25 years of R&D experience in big pharma (Johnson & Johnson companies), with various scientific leadership roles in preclinical drug discovery, translational research and clinical development. He contributed to the clinical development programs of several market-approved drugs, such as galantamine (Alzheimer's disease), telaprevir and simeprevir (hepatitis C). His scientific deliverables, reflected in over 150 co-authored peer-reviewed publications, span a variety of disease areas including infectious diseases, bone disorders, metabolic syndrome, gastroenterology, neuroscience, and oncology.

AHMET Ismayil

MD, PhD. After awarded PhD in cardiovascular surgery from Osaka University graduate school of Medicine in 2000 in Japan, I came to US and joined Laboratory of Cardiovascular Sciences, NIA, NIH as a post-doc fellow. Under leadership of Dr. Lakatta, I conducted preclinical research related to cardiovascular aging and age associated diseases, such as heart failure, hypertension, peripheral artery diseases, diabetes, Alzheimer's diseases and aortic aneurysms. I became a Staff Scientist in 2008. During last 24 years in NIA, I published more than 40+ papers and obtained a patent. Currently I am living in York County, Pennsylvania.



ALMUBARAK Bashayer

Dr. Bashayer Almubarak Ph.D., Director of Scientific Research at Hevolution Foundation. Dr. Bashayer holds a PhD in Neurosciences from the University of Edinburgh and a B.S. in Biochemistry from King Saud University. Dr. Bashayer has an extensive background in scientific research, having served in various capacities, primarily as a principal investigator, peer reviewer, and guiding scientific and ethical oversight by serving in IRB committees. Her enthusiasm for team and open science is evident in her numerous national and international collaborations as well as her commitment to disseminating research findings across a broad range of platforms.

ANDRIEU Sandrine

Sandrine Andrieu, MD, PhD - Professor of Public Health, Clinical Epidemiology and Public Health Department, IHU HealthAge, Toulouse (France). Sandrine Andrieu is professor of public health of the clinical epidemiology and public health department at the Toulouse University Hospital (France) and adjunct professor at the University of New Mexico (United States). Since 2009 she has been in charge of the Aging Research team at the Center for Epidemiology and Research in Population Health. She served as the Director of the Research Center for Epidemiology and Research in Population Health (UMR1295 INSERM - University Paul Sabatier) from 2011 to 2020. She has published more than 300 international papers and book chapters in the field of aging. She is involved in large prevention studies in neurodegenerative diseases (GuidAge, MAPT) and in European projects (HATICE study, MIND-AD, PRODEMOS). Her main topic of

reserach is Alzheimer's Disease and prevention of age-related loss of functions and healthy aging. She is the past president of the French National Society of Geriatrics and Gerontology.

ARMSTRONG Jenel

I am a 3rd-year PhD student in the Computational Biology and Bioinformatics program at Yale University, where my research focuses on the biology of aging using DNA methylation (DNAm) data and machine learning techniques. My work aims to develop reliable biomarkers of biological aging that predict age-related health outcomes, such as frailty, a syndrome associated with increased vulnerability to stressors and poor health outcomes. By leveraging large, diverse cohorts and advanced statistical approaches, I am refining DNAm biomarkers to better predict frailty and resilience, as well as improve our understanding of how aging interventions affect individual responses. Additionally, I am developing predictive models that can assess how people will respond to various anti-aging treatments, from lifestyle changes to pharmacological therapies. My research bridges molecular aging biomarkers with clinical markers, striving to provide a foundation for personalized medicine strategies that promote healthy aging and resilience in older adults. The ultimate goal of my work is to enhance the translation of these biomarkers into clinical settings, helping clinicians make informed decisions about aging-related diseases and interventions.

AUBERTIN-LEHEUDRE Mylène

Dr. Aubertin-Leheudre is a full professor-researcher at UQAM/CRIUGM and holds a Tier 1 Canada Research Chair (CIHR). She is also Associate Director of Clinical Research at the Centre de Recherche de l'Institut Universitaire de Gériatrie (CRIUGM) and Scientific Advisor to the FRQS (Fonds de Recherche en Santé du Québec). She holds more than $6 million in grants as a nominated PI and has published more than 150 articles. Since 2009, her research program aims to understand better how muscle function can be improved and maintained throughout the lifespan. Her empirical work focuses on 1) changes in muscle function & mobility that occur with normal aging and; 2) identifying the determinants of muscle function & mobility across the lifespan (e.g., lifestyle habits, physical fitness, chronic diseases, nutritional supplementation, adipose tissue etc.). Overall, her research examines the effects of adapted physical activity training and sedentary behavior on muscle function in older adults across the lifespan.

BARCONS Núria

Núria Barcons is a Registered Dietitian Nutritionist (RND) and holds a bachelor's degree in Human Nutrition and Dietetics from the University of Navarra (Spain). She works as a Global Medical Affairs Lead for Adult Medical Care at Nestlé Health Science. She is responsible for Medical Leadership, Medical education and Communication, and Real World Evidence generation for the Oral Nutritional Supplements (ONS) and Dysphagia portfolios at a global level. She has more than 20 years of experience in the pharmaceutical industry as a Medical Affairs in the field of disease-related malnutrition.

BIGOT Claire

Research Scientist – Business developer - Physiogenex. Claire is a Pharmacist holding a Ph.D in Immunology from the University of Toulouse III. Starting her career in the pharmaceutical industry, Claire worked as a Scientific Training Manager in Zambon, where she led national training programs in pharmacology. She then joined the R&D department of Baxter in Belgium, as a Stability Analyst directing stability studies on renal solutions. In her research career, Claire worked as a Research Assistant at the University of Florida, conducting cell culture and animal experiments on osteoclastogenesis. As a master's researcher at the Institute of Cardiac and Metabolic Diseases, she explored cardiac adaptations in female mice using advanced imaging techniques. During her PhD in the Institute of Pharmacology and Structural Biology, she focused on immunology, developing novel tools for measuring cellular forces during macrophage phagocytosis. Claire has also mentored students and professionals and taught physiology at the Faculty of Medicine. Claire works as a Study Director to perform preclinical studies in metabolic disorders (obesity, diabetes) and related co-morbidities for customers; or for Physiogenex' s internal research programs, focusing on aging. She also contributes to the business development through presentations of Physiogenex' s latest findings in international conferences.

BARUCH Amos

Dr. Amos Baruch earned his Ph.D. in Biochemistry and Cell Biology from Tel Aviv University in 1998. Following his graduation, he relocated to the United States for postdoctoral research, first at the Scripps Research Institute and then at the Department of Biochemistry and Biophysics at UCSF. His career progressed at Celera Genomics, where he headed the Chemical Proteomics Group. In 2006, Dr. Baruch's career took a pivotal turn when he joined KAI Pharmaceuticals. There, he led preclinical research efforts that culminated in the discovery of Parsabiv® (etelcalcetide), which is now a treatment for end-stage renal disease. Dr. Baruch spent the next decade at Genentech, leading Translational Medicine efforts and advancing Biomarker Development in cardiovascular disease, metabolism, and neurodegeneration. Currently, Dr. Baruch is at the helm of the Biomarker Department at Calico Life Sciences in South San Francisco, CA, where his team is dedicated to pioneering Biomarker Science for the study of aging and age-related diseases in humans.

BAUER Scott

Dr. Bauer is a general internist, translational epidemiologist, and clinician investigator with a primary care practice based at the San Francisco Veterans Affairs Medical Center (SFVAMC). He is also a member of the Baker Aging Research Institute (https://geroscience.ucsf.edu) and the Kidney Health Research Collective (https://khrc.ucsf.edu/). His academic focus is to understand the mechanisms underlying urologic aging and to define clinical phenotypes and biomarkers for older adults with debilitating urologic conditions. Dr. Bauer's areas of research expertise include geriatric urology, lifestyle and age-related risk factors, and longitudinal assessment of biomarkers, functional and quality of life outcomes, and, more recently, geroscience trials for age-related urologic dysfunction and symptoms.



BRONDELLO Jean Marc

Dr Jean-Marc Brondello (Eng-Ph.D-HDR) is an accomplished researcher specializing in cellular biology, senescence, and regenerative medicine. He earned his PhD at Nice University (France) by studying the role of MKPs in cell proliferation. He undertook postdoctoral research at The Scripps Research Institute in California, focusing on DNA damage checkpoints and cell cycle regulation. As INSERM research scientist, he currently heads the research group on "Senescence and Innovative Senotherapeutic Strategies Applied to Regenerative Medicine" at the Institute for Regenerative Medicine and Biotherapy (IRMB) in Montpellier. As part of the elective AGEMED national consortium on aging studies, his team aims to develop targeted treatments for degenerative diseases like osteoarthritis by focusing on senescent cells, offering potential alternatives to surgical interventions. Finally, JM Brondello plays an active role in academia, co-managing master's programs at Montpellier University and contributing to international conferences on aging, cellular biology, and regenerative medicine.

CANEVELLI Marco

I am currently an Assistant Professor of Neurology at the Department of Human Neuroscience, Sapienza University of Rome, Researcher at the Italian National Institute of Health, and Visiting Assistant Professor at the Aging Research Center, Karolinska Institutet. I am a member of the Scientific Committee of the Italian Society for the Study of Dementia (SINdem), secretary of the Italian Society of Neurogeriatrics, and Member of the Italian Dementia National Plan Working Group. I am the principal investigator of the «Dementia in immigrants and ethnic minorities living in Italy: clinical-epidemiological aspects and public health perspectives» (ImmiDem) project. I am the Editor-in-Chief of the Journal of Frailty & Aging and a member of the editorial board of JAMDA and the Journal of Nutrition Health & Aging. My main research interests deal with the epidemiology of cognitive disorders, frailty in dementia and other neurological diseases, and dementia in migrants.

CASDIN Alexander

Alex Casdin is Chief Executive Officer at Epirium Bio, and a member of the Board of Directors. He previously served as Chief Operating Officer and Chief Financial Officer. Alex has broad operational and financial expertise, with more than 25 years' experience as a successful healthcare executive and institutional investor. Before joining Epirium, Alex was the founder, Chief Executive Officer, and Portfolio Manager of Reneo Capital Management LP, Chief Financial Officer of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Earlier in his career he served in various management roles at healthcare investment funds. Alex serves on the Board of Directors of Erasca, Inc., and is Chair of the Audit Committee. He served on the Boards of Directors of Ignyta Inc. (acquired by Roche) and Dusa Pharmaceuticals, Inc. (acquired by Sun Pharma). He also served as an Investor Board Observer of 454 Life Sciences (acquired by Roche). Alex is a member of Brown University's President's Council on Biology and Medicine, and Treasurer, Executive Committee member of The American Society of Clinical Oncology's Conquer Cancer Foundation. He received an M.B.A. from Columbia Business School, Beta Gamma Sigma, and a B.A. in political science from Brown University.

CESARI Matteo

Dr. Matteo Cesari is a geriatrician, working as a Scientist (Geriatrics & Gerontology) in the Ageing and Health Unit at the World Health Organization (WHO; Geneva, Switzerland). He is also a Professor of Geriatrics (currently on leave) at the University of Milan (Italy), where he directed the Geriatric Fellowship program before joining the WHO in 2022. Dr Cesari's research activities have always been focused on the management of geriatric syndromes, in particular the frailty condition, and on strategies aimed at preventing the onset of functional impairment in older people. His research activities have been funded by major private and public institutions (e.g., European Commission, Innovative Medicines Initiatives, US National Institute on Aging, Velux-Stiftung Foundation, French Agence Nationale de la Recherche). Dr Cesari has published more than 650 articles in scientific peer-reviewed journals in the field of geriatrics and gerontology. He has served as Editor-in-Chief/Associate Editor in several peer-reviewed scientific journals and coordinator of task forces and working groups for scientific societies.

DAIMIEL Lidia

Dr. Lidia Daimiel holds a PhD in Biology and serves as the leader of the Nutritional Control of the Epigenome Group at IMDEA Food. Her research is focused on uncovering the molecular

mecha-nisms by which nutrients influence the cellular epigenome and how this knowledge can be applied to prevent chronic-metabolic non-communicable diseases and promote healthy aging. With ex-tensive expertise in studying molecular hallmarks of aging and microRNAs, she has led numerous human nutritional intervention trials. As the principal investigator of renowned clinical trials such as PREDIMED-Plus and ENSATI, Dr.Lidia Daimiel has contributed significantly to advancing the field. She has authored over 140 papers in prestigious peer-reviewed journals including JAMA, AJCN, Diabetes Care, EMBO Molecular Medicine, and Nature Communications, with an h-index of 31. Dr. Lidia Daimiel is an active member of prominent international consortia such as DIMENSION, EIT-Food Healthy Aging Think and Do Tank, AtheroNET COST, and SENESCENCE2030 COST. In addition to her research, she is an associate professor at Universidad San Pablo CEU and a member of va-rious scientific societies including the Sociedad Española de Nutrición and the American Society for Nutrition. Dr. Lidia Daimiel has supervised five doctoral theses and more than ten master's and degree projects

DE SOUTO BARRETO Philipe

Philipe de Souto Barreto is Professor of Gerontology (Université Paul Sabatier Toulouse 3) and coordinates the Institute on Aging at the Gerontopole, Toulouse University Hospital (WHO Collaborating Center on Frailty, Clinical & Geroscience Research & Geriatric Training). PhD in Bio-cultural Anthropology, he has leaded and participated in international taskforces, particularly on topics related to exercise and frailty. Philipe contributed to several national and international research projects as PI, local PI, and co-investigator (including the INSPIRE platform on Geroscience). Dr Barreto has been invited speaker at national and international congresses and has published hundreds of papers in prestigious Journals. He is Editor-in-Chief of the Journal of Nutrition, Health & Aging»

DIOH Waly

PhD, MBA, Chief Clinical Operations Officer-Biophytis. Molecular Biologist with many years of experience in Biotechnology, especially in the development of drug candidates targeting muscular disorders including age-related sarcopenia. I have been participating to the ICFSR congress and the Sarcopenia Task force in the past 10 years. I coordinated the Sarcob program (a public-private consortium dedicated to Sarcopenic Obesity) that led to the development of numerous drug candidates, to their characterization in cellular and animal models and to a better understanding of their putative mechanism of action through MAS receptor activation. I strongly contributed to the conduct of Biophytis SARA (SARcopenia and sarcopenic obesity in patients Aged ≥ 65 years) program. The SARA clinical development program composed of the completed phase 1 study and SARA-OBS, the 6-month observational study and SARA-INT, the interventional double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of two oral doses of BIO101. The Program is currently moving to a Phase 3 in older sarcopenic patients.

DUQUE Gustavo

Professor Gustavo Duque, MD, Ph.D., FRACP, is a geriatrician and biomedical scientist with a research interest in the mechanisms, potential therapies, and biomarkers for age-related bone loss, osteoporosis, sarcopenia, osteosarcopenia, and frailty in older persons. He is also looking at the effect of vitamin D, exercise, and proteins on bone and muscle mass. His initial training included Internal Medicine at Javeriana University (Colombia) and Geriatric Medicine, which he completed at McGill University in Montreal (Canada). Subsequently, he obtained his Ph.D. at McGill University in 2003 with a thesis entitled 'Molecular Changes of the Aging Osteoblast' under the supervision of Dr. Richard Kremer. Between 2003 and November 2007, he joined the McGill University Medical School faculty as a member of the Division of Geriatric Medicine and as a Researcher at the Lady Davis Institute for Medical Research. In November 2007, he moved to Australia to join the Faculty as Associate Professor and Head of the Division of Geriatric Medicine and Director of the Musculoskeletal Ageing Research Program at Sydney Medical School Nepean -University of Sydney. In 2012, he was promoted to Professor of Medicine at the University of Sydney. Between 2015 and 2022, Professor Duque held the positions of Chair of Medicine and Director of the Australian Institute for Musculoskeletal Science at the University of Melbourne. In 2022, Prof. Duque assumed the roles of Full Professor, Dr. Joseph Kaufmann Chair in Geriatric Medicine, Director - RUISSS McGill Centre of Excellence for Sustainable Health of Seniors/ Simone & Edouard Shouela (CE-Durable), and Principal Investigator at the Bone, Muscle & Geroscience Group of the Research Institute of the McGill University Health Centre (MUHC). He is also the Editor-in-Chief of the Journal of Gerontology: Biological Sciences, one of the official journals of the Gerontological Society of America. As a Geriatrician and Clinician-Investigator, Prof. Duque has implemented several Falls and Fractures clinics (the most recent ones at the MUHC and the Jewish General Hospital in Montreal) where patients are comprehensively assessed for falls and fracture risk. His clinical trials unit conducts several trials testing the effect of pharmacological and non-pharmacological treatments for age-related musculoskeletal diseases. He is the author of more than 280 peer-reviewed articles and multiple book chapters and has edited five books in the aging and musculoskeletal fields (two on osteosarcopenia).

FEIGE Jerome

Dr Jerome N. Feige is the head of the Physical Health department and vice-director of the Nestlé Institute of Health Sciences in Lausanne, Switzerland, and a recognized expert in muscle

and aging biology. He holds a degree in Bioengineering and a PhD in Biology from the University of Lausanne. Dr Feige performed post-doctoral research at the Institute of Genetics, and Molecular and Cellular Biology in Strasbourg, France on the molecular regulation of energy metabolism. He subsequently worked as laboratory head at the Novartis Institute of Biomedical Research in Basel, Switzerland, where he performed drug discovery for muscle diseases and contributed to the development of new therapies. Since 2012, Dr Feige has held increasing responsibilities in the Nestlé Institute of Health Sciences where he established a research program studying muscle biology and a translational department developing nutritional therapies to support the Musculo-Skeletal system. His research programs have lead to the commercialization of several products for infant and medical nutrition, and to the creation of 2 start-ups. Dr Feige is also an adjunct lecturer at the Ecole Polytechnique Fédérale de Lausanne (EPFL) where he teaches nutrition and entrepreneurship, and trains PhD students in biomedical science.

FERRIOLLI Eduardo

Eduardo Ferriolli is a Professor of Geriatric Medicine at the Division of Geriatrics of the Department of Internal Medicine at the University of Sao Paulo Medical School, Sao Paulo, Brazil. He is the coordinator of the NAPENV – Center for Research on Aging and the Older People at the University of Sao Paulo and coordinator of the LIM-66 – Laboratory of Medical Research on Aging at the Clinics Hospital of the University of São Paulo Medical School. He previously coordinated the FIBRA – Frailty in Brazilian Older Persons study, which evaluated the presence of the Frailty Syndrome in about 5000 older persons from all regions of Brazil. He also coordinated a study on sarcopenia in Latin America and the Caribbean, with the participation of 13 countries of the region and sponsored by the International Atomic Energy Agency, with final data in preparation for publication. Consultant for the World Health Organization and the Pan American Health Organization for Intrinsic Capacity and ICOPE (Integrated Care for Older People). He is presently leading the ICOPE-BR study, a multicenter study on Intrinsic Capacity and the ICOPE Screening Tool involving 20 Brazilian universities in all Brazilian Regions, and that will include more than 4000 older participants. He has 176 publications, 2,201 citations and an H-index of 28 (Web of Science)



FERRUCCI Luigi

Dr. Luigi Ferrucci is a geriatrician and an epidemiologist who conducts research on the causal pathways leading to progressive physical and cognitive decline in older persons. He has made major contributions in the design of many epidemiological studies conducted in the U.S. and in Europe. Dr. Ferrucci received a Medical Degree and Board Certification in 1980, Board Certification in Geriatrics in 1982 and Ph.D. in Biology and Pathophysiology of Aging in 1998 at the University of Florence, Italy. Between 1985 and 2002 he was Chief of Geriatric Rehabilitation at the Department of Geriatric Medicine and Director of the Laboratory of Clinical Epidemiology at the Italian National Institute of Aging. In September 2002, he became the Chief of the Longitudinal Studies Section at NIA. From 2002 to 2014 he was the Director of the Baltimore Longitudinal Study on Aging. Dr. Ferrucci is currently the Scientific Director of NIA, since May 2011.

FIELDING Roger

Roger A. Fielding, Ph.D. serves as Team Lead and Senior Scientist of the Nutrition, Exercise Physiology, and Sarcopenia (NEPS) Team at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. He is also Professor of Nutrition at the Friedman School of Nutrition Science and Policy, Professor of Medicine at Tufts University School of Medicine and the Associate Director of the Boston Claude D. Pepper Older Americans Independence Center. Dr. Fielding is an internationally known researcher who studies the underlying mechanisms contributing to the age-associated decline in skeletal muscle mass, the resultant impact on function, and the potential role of exercise, nutrition, physical activity and other therapies on attenuating this process. He has published over 250 peer-reviewed papers(H-index 101). Dr. Fielding has a strong record of extramural funding including support from the NIH, USDA, foundations and industry. He is an Deputy Editor of the Journals of Gerontology Medical Sciences, and Calcified Tissues International and Musculoskeletal Research. He has also served as a reviewer on numerous NIH study sections and was elected to the NIH/CSR College of Reviewers. In 2015, he received the Olof Johnell Science Award from the International Osteoporosis Foundation and in 2021 he received the Herbert Fleisch Medal from the same organization.

GOMEZ CABRERA Maria Carmen

Maria Carmen Gómez Cabrera is a full professor in the Department of Physiology at the Faculty of Medicine, University of Valencia. Her research focuses on the physiology of skeletal muscle and the mechanisms underlying muscle dysfunction, including the loss of strength and muscle mass associated with aging, periods of immobilization or physical inactivity, and certain pathological conditions. Her team develops interventions—primarily nutritional and exercise-based, and in some cases pharmacological—aimed at improving muscle function and enhancing the quality of life in the elderly. She serves as the principal investigator of the Research Group on Exercise, Nutrition, and Healthy Lifestyle at the INCLIVA Health Research Institute in Spain.Maria Carmen is the author of over 140 peer-reviewed international publications in high-impact journals. Her contributions to the fields of exercise redox biology, healthy aging, frailty, and sarcopenia have garnered more than 14,000 citations, reflecting an h-index of 50.

GUTIERREZ ROBLEDO Luis Miguel

Dr. Luis Miguel Gutiérrez Robledo is a Mexican geriatrician and epidemiologist with a distinguished career spanning four decades. He has held leadership positions at prestigious institutions, including the Geriatrics Department created and led by him during 20 years at the National Institute of Medical Sciences; he became later on the founding director of the National Institute of Geriatrics in Mexico. His research focuses on models of care, Alzheimer's disease, and the epidemiology of aging. He has authored more than 300 publications with 21,000 citations and an H index of 55. He is a member of the National Academies of Medicine of Mexico and France. Dr. Gutiérrez has been appointed by WHO as one of the 50 global healthy aging leaders.

GUYONNET Sophie

Sophie Guyonnet is a Biologist (PhD, HDR) specialized in Nutrition and Aging Research, Associate Professor at the IHU HealthAge, Gérontopôle/Toulouse University Hospital Department of Geriatric Medicine, University Toulouse III, CERPOP (Center for Epidemiology and Research in Population Health, UMR1295 INSERM (Aging Team). She is Responsible for the development of the Gerontopole Cinical Research programs, including design and execution of trials, regulatory procedures, budget, timelines, and communicating with key internal and external stakeholders. It field of expertise includes National and European coordination of large multicentric cohort of patients with Alzheimer Disease (REAL.FR study, PLASA study); National coordination of large multicentric preventive trials in the field of neurodegenerative diseases (MAPT, MAPT PLUS, NOLAN); Coordination of human biobanks (MAPT, NOLAN, INSPIRE-T); Nutritional factors, cognition and prevention of neurodegenerative diseases; Nutritional factors and prevention of intrinsic capacity decline; Multidomain approach. Since 2019, She is in charge of the management of the Inspire Bio-resource Research Platform for Healthy Aging; the main objective of this platform is to build a comprehensive research platform gathering biological, clinical (including imaging) and digital resources that will be explored to identify robust (set of) markers of aging, age-related diseases and intrinsic capacity evolution. One of the most challenge of the Inspire Platform is the implementation of a Human Translational Research cohort (INSPIRE-T cohort) and animal cohorts in mirror. Since 2024, she is the program director of the Institut Hospitalo-Universitaire (IHU) HealthAge on healthy longevity, prevention and gerosciences.



HASCUP Kevin

Kevin Hascup, Associate Professor in the Dale and Deborah Smith Center for Alzheimer's Research and Treatment at Southern Illinois University School of Medicine, is an experienced neuroscientist with expertise in Alzheimer's disease (AD), cell senescence, and glutamatergic neurotransmission. Prior to joining the faculty, Dr. Hascup completed fellowships at the Karolinska Institute and McGill University. Currently, Dr. Hascup leads a team of scientists using geroscience approaches to understand the biological processes contributing to AD pathogenesis. His team has discovered sex-specific differences in hippocampal glutamatergic neurotransmission and the accumulation of senescent cells in the brain and adipose tissue of amyloid-specific AD mouse models. Furthermore, the effects of drugs modulating glutamate signaling or senescent cell burden in both normal aging and AD mouse models differ based on sex and disease state. The long term goal of this research is to identify sex and disease-stage specific interventions that can delay or ameliorate cognitive deficits. This novel research has led to extramural funding from the State of Illinois and the National Institutes on Aging. Dr. Hascup's scholarship record includes over 40 peer-reviewed articles and 70 scientific abstracts.

HIGGINS-CHEN Albert

Albert Higgins-Chen is an Assistant Professor in the Department of Psychiatry at Yale University where he is a principal investigator. During his MD/PhD training at the University of Michigan, he worked with C. elegans identifying genes regulating aging and longevity. He is a clinically trained psychiatrist and has applied aging biomarkers to investigate how mental health and treatment affect aging. He now develops new methods for measuring the biological aging process and the effects of aging interventions

HUISINGH-SCHEETZ Megan

As a Geriatrician with a Master's degree in Epidemiology, I have focused my career on the translation and advancement of frailty science. I have a specific interest in understanding the role of technology in advancing translational frailty science. My work targets two areas of technology: accelerometry and voice-activated assistant devices. I study how accelerometry-based mobility patterns relate to frailty and aging biomarkers and whether these devices can improve our understanding of frailty, enhance the frailty assessment and support frailty management. I have identified novel accelerometry patterns predictive of frailty, physical function, disability, inflammation, social engagement and cognition. I have analyzed accelerometry data from the National Social Life, Health and Aging Project (NSHAP), the National Health and Nutrition Examination Survey as well as my longitudinal, primary accelerometry data (n=151) collected in predominantly African-American older adults. As a clinician, I established a novel frailty evaluation clinic in 2011, the Successful Aging and Frailty Evaluation™ (SAFE) clinic, in which I assess and manage frailty in all referred patients and support their caregivers. This clinical experience informed my "in the trenches" perspective on the value of and remaining challenges to frailty

measurement in practice. My clinical work inspired me to develop a new technology-based program called "EngAGE" that leverages a voice-activate assistant to deliver long-term exercise and socialization support to frail adults while empowering their caregivers. I am currently leading a randomized-controlled trial testing EngAGE's efficacy on physical and social function among multimorbid, homebound, African-American older adults.

ITOH Sakiko

Dr. Sakiko Itoh is an associate professor at the Institute of Science Tokyo, Japan. Her research focuses on Community-based Care for older adults, Public Health Informatics, and Nursing Informatics. She earned her Ph.D. from Tokyo Medical and Dental University, following hands-on experience as a public health nurse in local government. Dr. Itoh's work bridges the gap between research and practice, with a strong focus on developing and improving care systems for aging populations. In her most recent publication, Dr. Itoh analyzed a large-scale dataset on long-term care and health care, revealing that advanced care management groups had significantly lower rates of home-help service and community-based day care service use compared to conventional care management groups. These findings have important implications for optimizing resource allocation and improving care outcomes in aging societies. Dr. Itoh has collaborated with interdisciplinary teams both nationally and internationally, contributing to innovative approaches in geroscience and informatics. She has presented her research at over 40 conferences and published in more than 30 peer-reviewed journals. Passionate about integrating technology and data-driven solutions into public health strategies, Dr. Itoh is committed to enhancing the quality of life for older adults. She is an active member of several professional organizations, including the Japan Academy of Home Care, the Japan Association for Medical Informatics, and the Gerontological Society of America.
TOH Sakiko, RN, PHN, PhD, Associate Professor, Graduate School of Health Care Sciences, Institute of Science Tokyo
1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, JAPAN Email: itoh.sakiko@tmd.ac.jp

JUSTICE Jamie

Dr. Jamie Justice, PhD, is Executive Director of XPRIZE Healthspan Prize and EVP of Health Domain at XPRIZE Foundation, and an Adjunct Professor in Internal Medicine Section on Gerontology and Geriatric Medicine, and Sticht Center on Healthy Aging and Alzheimer's Prevention at Wake Forest University School of Medicine (WFUSM). Jamie completed graduate and postdoc training at University of Colorado Boulder and WFUSM. At WFUSM Jamie was director the Biogerontology Lab, and co-leader the Integrative Biology Core (IBC) of the WF Claude D. Pepper Older Americans Independence Center (OAIC), and an MPI of the National Institute of Aging-supported Geroscience Education. Jamie was the recipient of the Jarrahi Research Scholars Fund in Geroscience Innovation, the 2022 Vincent Cristofalo Rising Star in Aging Research, and the 2022 NIA Nathan W Shock Awardee. Jamie is dedicated to geroscience which that advances the hypothesis that by targeting the basic biology of aging the incidence of multiple age-related diseases can be delayed or prevented. Her training background allowed her lead translational research to test the geroscience hypothesis in humans. This included: 1) serving as Co-I on large multicenter prospective cohort studies like the Study of Muscle Mobility and Aging (SOMMA), and the NIH Cell Senescence (SenNet) Buck Institute Tissue Mapping Center for skeletal muscle; 2) leading proof-of-concept senolytics trials; and 3) designing trials of testing therapeutics that target biological age in older adults. In her new role as Executive Director of the $101M XPRIZE Healthspan she operates a $101 million global competition to drive teams to develop innovative solutions that make healthy human aging possible, for everyone.

KIPROV Dobri

He is a Harvard trained immunologist. He is an internationally recognized pioneer in the field of apheresis and has more than 100 publications on the subject. He has served two terms on the Board of Directors of American Society For Apheresis and is currently a member of the Board of Directors of the International Society of Apheresis and is a member of the editorial board of the Journal of Transfusion and Apheresis Science. He has received multiple awards for his contributions to the field of apheresis and has served as Chairman of the Division of Immunotherapy at California Pacific Medical Center. He was the founder and President of the Bay Area Mobile Apheresis Program and Senior Vice President and Medical Director for Apheresis for Fresenius Medical Care, NA. Recently, DK founded Global Apheresis and co-founded Lyfspan, a company devoted to the research of aging. He is also a senior visiting scientist at the Buck Institute for the Research of Aging. Dr. Kiprov pioneered the use of Therapeutic Plasma Exchange (TPE) in ameliorating the effects of aging and is conducting a number of controlled and uncontrolled studies. The early results are already published.

KONOPKA Adam

PhD. Adam Konopka is an Assistant Professor of Medicine in the Division of Geriatrics and Gerontology at the University of Wisconsin-Madison. The overall theme of Dr. Konopka's laboratory is to use a translational research approach to understand the mechanisms involved in the pathogenesis and treatment of aging and age-related disease. A major goal of his laboratory is to take findings from tissue culture, rodents, and non-human primates and test in human clinical trials. Dr. Konopka has several ongoing studies to test the if mTOR inhibition by rapamycin can modify the biology of aging and improve clinically relevant physiological outcomes in humans and animal models.

KROEMER Guido

Guido Kroemer is currently Professor at the Faculty of Medicine of the University of Paris-Cité, Director of the research team «Metabolism, Cancer and Immunity» of the French Medical Research Council (INSERM), Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Comprehensive Cancer Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France. Dr. Kroemer's work focuses on the pathophysiological implications of cell stress and death in the context of aging, cancer and inflammation. He discovered the ignition of regulated cell death pathways by mitochondrial membrane permeabilization, the cytoprotective and antiaging effects of macroautophagy, as well as the decisive role of immunogenic cell death in anticancer treatments. Dr. Kroemer is member of the Academia Europaea, Austrian Academy of Sciences, Chinese Academy of Engineering, European Academy of Cancer Sciences, European Academy of Sciences, European Academy of Sciences and Arts, European Molecular Biology Organization, German Academy of Sciences (Leopoldina), Institut Universitaire de France and Royal Spanish Academy of Sciences. He is the President of the European Academy of Tumor Immunology and the European Network for Cancer Immunotherapy.

KUCHEL George

George A. Kuchel MD CM is a geriatrician and translational geroscientist at the University of Connecticut in Farmington, CT, USA. George Kuchel was born in Czechoslovakia, and grew up in Montreal, Quebec, Canada where he graduated from McGill Medical School. Dr Kuchel is a professor of medicine, he holds the Travelers chair in Geriatrics and Gerontology. He serves as director of the UConn Center on Aging at UConn Health in Farmington, CT. His research has focused on interventions designed to enhance function and independence in older adults by targeting shared biological mechanisms involved in host defense, mobility, cognition and continence. He leads a NIA Claude D. Pepper Older Americans Independence Center at UConn, one of only 15 such centers of excellence in the US. Dr Kuchel is also PI of the NIA Geroscience Education and Training Network, the NIH Common Fund KAPP-Sen Cellular Senescence Tissue Mapping Center, and multiple PI of the NIA Translational Geroscience Network.

LeBRASSEUR Nathan

Nathan LeBrasseur, PT, PhD, is a Professor in the Department of Physical Medicine and Rehabilitation and has a joint appointment in the Department of Physiology and Biomedical Engineering at Mayo Clinic. Dr. LeBrasseur is the Director of the Robert and Arlene Kogod Center on Aging, the Co-Director of the Paul F. Glenn Center for Biology of Aging Research, and Scientific Director of the Office of Translation to Practice at Mayo Clinic. He is the recent chair of the NIH Cellular Mechanisms in Aging and Development Study Section. Dr. LeBrasseur's research team conducts translational "bench-to-bedside" research on strategies to improve physical function, metabolism, and resilience in the face of aging and disease. His latest work has centered on cellular senescence, a fundamental mechanism of aging, and interventions to counter this process to extend healthspan. Dr. LeBrasseur has received the Glenn Award for Research in Biological Mechanisms of Aging, the Nathan W. Shock Award Lecture from the National Institute on Aging, and the Vincent Cristofalo Rising Star Award in Aging Research from the American Federation for Aging Research. He is a Fellow of the Gerontological Society of America.

LEE Tatia

Tatia Lee is the Chair Professor of Psychological Science and Clinical Psychology and holds the May Endowed Professorship in Neuropsychology at The University of Hong Kong. Her research focuses on the neuroplastic mechanisms that explain normal and pathological neurocognitive and affective processes during ageing. Professor Lee has published over 340 papers. She has received significant recognition nationally and internationally for her outstanding contributions to the advancement of science. She has been elected as a Fellow of esteemed international societies, including the UK Academy of Social Sciences and the World Academy of Sciences.

LEE Yuta

Yuta Lee is the founder and CEO of Accelerated Bio, a regenerative medicine company based in Philadelphia commercializing the human Trophoblast Stem Cell (hTSC). hTSCs are the earliest embryonic-staged stem cells that can be sourced ethically from an ectopic pregnancy. These naïve cells can scale to 85 population doublings with natural immune privilege, making them the most ideal starting cell source for allogeneic cell & gene therapies. The hTSC platform has been awarded 58 patents, providing freedom-to-operate for partners looking for a clear pathway to commercialization. Yuta is passionate about accelerating cell & gene therapies to advance healthspan. Accelerated Bio recently collaborated with the National Institute on Aging (NIH) using hTSC exosomes for Cell Senescence and is looking to frailty and sarcopenia as potential clinical indications. Yuta has dual B.A. degrees in economics and legal studies from the University of California, Berkeley. Yuta earned his EMBA in 2009 from China Europe International Business School (CEIBS) in Shanghai, China and graduated with the Outstanding Graduate of the Year Award.

MA Lina

Lina Ma, Professor, Chief Physician, National Clinical Research Center for Geriatric Diseases, Beijing, China. Lina Ma, M.D., Ph.D., is the deputy director of the Department of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases. She was awarded the AGS New Investigator Award and EURASIA-PACIFIC UNINET Scholarship in the past several years. She is a member of Gerontological Society of America (GSA) and American Geriatrics Society (AGS). Her contribution to science included clinical studies on frailty, intrinsic capacity and chronic diseases in old adults and translational research in translating basic aging related biological findings to clinical work. Her recent publications include more than 90 SCI journal articles focusing on aging and frailty. As principal investigator, she has several research grants including Natural Science Foundation of China. Her original research findings have been presented in international conferences such as IAGG World Congress of Gerontology and Geriatrics, GSA, AGS and ICFSR.

MADHAVAN Sidharth

Sid is a graduating Ph.D. candidate under Dr. John Newman in the Biology of Aging program through the University of Southern California and Buck Institute for Research on Aging. His doctoral work with Dr. Newman characterized the role of ketone bodies as regulators of cellular proteostasis in the aging brain. This work was recently published in Cell Chemical Biology. After graduation in May 2025, he will join Duke University for a postdoctoral fellowship under Dr. Laurie Sanders and Dr. Senthil Selvaraj. Here, he will continue to work to develop exogenous ketones as a gerotherapeutic by designing and administering human clinical trials for age-related diseases, such as Alzheimer disease and heart failure.

MAHAJAN Ravi

Professor Ravi P Mahajan CBE, DM, FRCA, FCAI. *Current Positions*: * Director of Critical Care Integration and Transformation, Apollo Hospitals Group; * Director of Research and Innovations, Apollo Hospitals Group; * Emeritus Professor, Anaesthesia and Critical Care, Nottingham University, UK. Professor Mahajan is currently directing development of Enhanced and Comprehensive Connected Care as part of Pan-India quality improvement drive. *Relevant Previous Positions and Achievements*: * President, Royal College of Anaesthetists, UK; * Editor-in-Chief, British Journal of Anaesthesia; * Chairman, Safe Anaesthesia Liaison Group, UK; * Chairman, Patient Safety Committee, European Society of Anaesthesiology. Established international organisations such as National Institute of Academic Anaesthesia (NIAA), Health Services Research Centre (HSRC) and Centre of Perioperative Care (CPOC) in the UK; for these achievements he recently received honour of CBE (Commander of the order of British Empire) from King Charles. Co-authored 5 books and over 250 scientific publications in high impact international journals.

MAIER Andrea

Oon Chiew Seng Professor in Medicine, National University of Singapore. Co-Founder, NUS Academy for Healthy Longevity, National University of Singapore. Professor of Gerontology, Vrije Universiteit Amsterdam, The Netherlands. Founder, Chi Longevity. Andrea B. Maier (1978), a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. She was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016. From 2016 to early 2021 Professor Maier served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continued her career at the National University of Singapore as Director of the Centre for Healthy Longevity. Professor Maier's research focuses on unraveling the mechanisms of ageing and age-related diseases to bring diagnostics and interventions to optimize health into clinical practice. She is heading international longitudinal cohort studies and geroscience interventions. She has published more than 460 peer-reviewed articles, achieving an H index of 85, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs and book author to disseminate aging research. Furthermore, she is invited member and advisor of several international academic and health policy committees and funding agencies, including the World Health Organization evaluating the United Nations Decade of Healthy Ageing and Hevolution. In 2022, she co-founded the first evidence based Healthy Longevity Medicine Clinic in Singapore, Chi Longevity, and joined NU as Chief Medical Officer. She is the past President of The Australian and New Zealand Society for Sarcopenia and Frailty Research, the Founding President of the Healthy Longevity Medicine Society and serves as selected Member of The Royal Holland Society of Sciences and Humanities, Fellow of the Atria Academy of Science and Medicine, and Academy for Health and Lifespan Research. In 2023, she co-founded the NUS Academy for Healthy Longevity to disseminate Geroscience and evidence based Precision Geromedicine.

MANDER Anthony

Qualifications: MB ChB 1970 University of Sheffield. Distinction: Final MB ChB Dermatology, Venereology, Otolaryngology, Ophthalmology MRCOG; July 1975: Specialist Ac-

creditation February 1980: FRCOG; 1989: Mediator London School of Mediation Jan 2013. *Current appointment*: Consultant Gynaecologist -special interests Menopause, Health and Lifestyle: 1.Apollonia House Healthcare, Rochdale Road, Grasscroft, Oldham. OL4 4HA; 2.Nuffield Manor Hospital, Oxford. OX3 7BR. *Mediator*: * Associate Editor "Journal of Post Reproductive Health", Sage Publishing; * President of the Forum of Food and Health, Royal Society of Medicine, London. (2013 –15); * Honorary Fellow Institute of Cancer and Enabling Sciences, Medical School, Manchester. (Sept 2019). Principal Trainer for the Basic and Advanced Certificate in Menopause Care. (June 2020) Faculty of Sexual and Reproductive Healthcare, (RCOG)<; Expert Advisor Women's Health Concern. Brought up in Hathersage, in the Peak District in Derbyshire. Qualified in medicine at Sheffield with honours in Dermatology , ENT, Ophthalmology, Venereology. He is a trained mediator. Tony extensive interests in nutrition and the menopause published a number of books on this topic including " Managing the Menopause without Oestrogen". He is Associate Editor of "Post Reproductive Health" and actively involved in writing and reviewing. He has organised forum meetings on "Alzheimers from cradle to grave" "Longevity and lifestyle" and lectures regularly on post reproductive health at national and international level. Other interests include, cricket- playing for the "far from the madding crowd team "(FFTMCC), literature, history and maps.

MERCHANT Reshma

A/Prof Merchant is the head of Division of Geriatric Medicine at National University Hospital. Her expertise in healthy aging has made her a significant figure in geriatrics both locally and globally. She is a member of the Ministry of Health Frailty Implementation Workgroup, WHO Global Network on Long-term Care and Clinical Consortium on Healthy Ageing. Throughout her career, she has received multiple clinical and teaching awards, including the Distinguished Senior Clinician award in 2024 and the NUHS-Mochtar Riady Pinnacle Master Clinician Award in 2022. Her research focuses on sarcopenia, falls prevention, frailty, and healthy aging. She is well published, PI for population health grants and is involved in numerous ongoing population-level healthy aging programs, such as the Health District @ Queenstown and the Movement for Health initiative. She serves in multiple editorial boards and co-author in multiple global consensus papers.

MIR Nabiel

Nabiel Mir, MD, is an Instructor in Geriatric Oncology, a K12 Scholar, and an Elmwood V. Jensen Scholar at the University of Chicago. His research focuses on integrating geriatric assessments into oncology practice, developing predictive tools for treatment toxicity and frailty in older adults with solid malignancies, leveraging digital health technologies to enhance patient outcomes, and designing clinical trials to address both cancer and vulnerability in older adults. Dr. Mir's clinical efforts emphasize personalized care models that address biological and functional vulnerabilities in older adults with cancer at the University of Chicago Comprehensive Cancer Center (UCCCC). He plays a key role in improving post-acute care transitions and increasing the representation of older adults in clinical trials through the "UCCCC Older Adult Working Group," advancing the center's mission to achieve «Age-Friendly Health System» designation. His contributions to geriatric oncology have been recognized with notable awards, including the Bayer-Prostate Cancer Foundation Darolutamide Challenge Award and the Prostate Cancer Foundation Young Investigator Award. Dr. Mir's work demonstrates a commitment to enhancing cancer care for vulnerable populations through innovative research, clinical excellence, and collaboration across disciplines.

MOBASHERI Ali

Ali Mobasheri is Professor of Musculoskeletal Biology in the Research Unit of Health Sciences and Technology within the Faculty of Medicine at the University of Oulu in Finland. He also holds the position of Chief Researcher and International Adviser in the State Research Institute Centre for Innovative Medicine in Vilnius, Lithuania. Ali has served as President of the Osteoarthritis Research Society International (OARSI) and currently serves on the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). In addition, he holds the position of "Collaborateur Scientifique de l'Université de Liège" and Advisor to the World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging, Université de Liège, Liège, Belgium. He is a member of OARSI, the International Cartilage Regeneration & Joint Preservation Society (ICRS) and serves on the translational science committee of ICRS. He serves on the Editorial Board of Osteoarthritis and Cartilage Open (Elsevier) and Osteoarthritis Imaging (Elsevier) and several other journals. Ali's work focuses on cartilage biology, osteoarthritis, pain and biomarkers. He has published more than 400 scientific articles and has an h-index of 76 on Scopus.ORCID iD: 0000-0001-6261-1286 https://orcid.org/0000-0001-6261-1286. Scopus Author Identifier: 7003311894. https://www.scopus.com/authid/detail.uri?authorId=7003311894. Ali Mobasheri, BSc, ARCS, MSc, DPhil (Oxon), Professor of Musculoskeletal Biology, Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, .O. Box 5000, FI-90014, Oulu, Finland. E-mail: ali.mobasheri@oulu.fi https://www.oulu.fi/en/researchers/ali-mobasheri. https://www.oulu.fi/en/research-groups/biomarkers-and-immunometabolism-musculoskeletal-health-and-ageing. Finland Business Mobile Phone: 0294485631 (+358294485631) / 050 477 2985 (+358504772985), UK Mobile Phone: +447790824544. Finland Personal Mobile phone: +358403621579. ORCID iD: 0000-0001-6261-1286

MUSCEDERE John

Dr. John Muscedere MD, FRCPC is a Professor of Medicine, Intensivist and Clinician Scientist at Queen's University and Kingston Health Sciences Center. Dr. Muscedere' s research focuses on improving outcomes by generating new evidence and knowledge translation through clinical trials, systematic reviews and meta-analyses focussing on nosocomial infections and frailty. He is the Scientific Director for the Canadian Frailty Network (CFN). CFN is dedicated to improving care for older Canadians living with frailty through the generation of new knowledge, knowledge mobilization, partnerships and training highly qualified personnel. CFN is developing public health initiatives for the prevention and mitigation of frailty through Regional Centers for Healthy Aging. For more information: www.cfn-nce.ca

NEWMAN John

John Newman, MD, PhD is a geriatrician, basic scientist, and educator at the Buck Institute for Research on Aging and in the Division of Geriatrics at UCSF. His laboratory at the Buck Institute carries out basic science and clinical research investigating the energy and signaling functions of ketone bodies in the aging brain, Alzheimer's disease, and frailty. He also leads a clinical-translational program to understand how aging-related metabolic mechanisms drive the geriatric syndrome delirium. He is a member of the Bakar Aging Research Institute at UCSF and the UCSF Older Americans Independence (Pepper) Center, and a leader of the national Geroscience Education and Training Network

OLASO-GONZALEZ Gloria

Dr Gloria Olaso-González graduated in Chemistry (University of Valencia, 2003) receiving the Extraordinary Degree Award, and later earned a degree in Food Science and Technology (2007). Her scientific career began in Theoretical and Computational Chemistry at the Institute of Molecular Science (ICMol), focusing on photoinduced processes in biological systems. Her PhD, funded by an FPU scholarship, laid the groundwork for her transition to Biomedicine, where she has established a distinguished research profile. Currently, she is a Full Professor of Physiology at the University of Valencia. Her research focuses on molecular mechanisms of ageing and age-related diseases, with a special emphasis on nutritional interventions to promote healthy ageing. She is a core member of the FRESHAGE group at the University of Valencia, a researcher at CIBER (CB16/10/00435), and part of the INCLIVA Research Group on Exercise, Nutrition, and Healthy Lifestyle. She has authored 45 JCR-indexed publications (35 in Q1, 13 in D1) and contributed to 11 book chapters. She has led a regional and co-led a national research project, and participated in 18 research initiatives, including European projects. With 48 conference communications and a strong editorial presence, she continues to advance the understanding of ageing and its mitigation through lifestyle interventions.

ORR Miranda

Miranda E. Orr, PhD, is an Associate Professor of Neurology and co-director of the Tracy Family Stable Isotope Labeling Quantitation (SILQ) Center at Washington University in St. Louis, MO. With over 15 years of expertise in aging biology and neurodegenerative diseases, Dr. Orr is recognized for discovering a link between cellular senescence Alzheimer's disease pathogenesis, and for leading the first clinical trials of senolytics in Alzheimer's disease, including an on-going multi-site phase 2 trial. Her translational research integrates spatial biology technologies to map mouse and human brain tissue across the lifespan, offering new insights into disease mechanisms and therapeutic targets. In addition to publishing her research findings in top-tier scientific journals, her work has been featured in National Geographic, demonstrating its impact both within the scientific community and the broader public. Prestigious accolades include the inaugural Jarrahi Geroscience Scholar Award and the Melvin R. Goodes Prize for Excellence in Alzheimer's Disease Drug Development. Dr. Orr is also committed to multiple educational initiatives, including serving as co-investigator on the NIH-funded Geroscience Education and Training (GET) Network initiative, helping develop curricula for the next generation of geroscientists.



PASCO Julie

BSc(Hons), DipEd, PhD, MEpi. Chair, Epidemiology of Musculoskeletal and Metabolic Disorders in the School of Medicine at Deakin University, Australia; Director of the Epi-Centre for Healthy Ageing; and Leader for Population Health in IMPACT - the Institute for Mental and Physical Health and Clinical Translation. Her population-based health research focuses on understanding interactions between bone, muscle and fat, evaluating pathways associated with the progression of musculoskeletal disorders and frailty during ageing, and the nexus between physical and mental health. Member of the ANZSSFR Taskforce for Sarcopenia Diagnosis and Management in Australia and New Zealand, and the Global Leadership Initiative in Sarcopenia (GLIS). Leader of several population-based studies including the long-running and highly-successful Geelong Osteoporosis Study (GOS), a cohort study for men and women; the Vitamin D in Pregnancy study, and the Ageing, Chronic Disease and Injury study in western Victoria. Pasco has attracted $10 million in funding; she has 455 publications and an H-index 68 in Scopus (91 Google Scholar).

PEREIRA Suzette

Dr. Suzette Pereira, Ph.D. is a Research Fellow at the Nutrition Division of Abbott. Over her 20+ year tenure at Abbott, she has conducted both clinical and pre-clinical research towards developing novel nutritional products to address muscle loss due to aging (sarcopenia), chronic disease, hospitalization, and malnutrition. Her research has focused on understanding mechanisms behind muscle loss and identifying bioactive nutritional ingredients to mitigate the same. Together with her diagnostic colleagues she has also explored the development of novel technologies to screen and identify muscle loss towards increasing awareness with consumers and health care professionals. Prior to joining Abbott, Dr. Pereira received her doctoral degree and carried out postdoctoral research in Molecular Microbiology at The Ohio State University (USA). She has coauthored over 70 peer-reviewed manuscripts and ~230 patents/patent applications.

RAGHAVAN PILLAI Raju

Dr. Raghavan Pillai Raju is a tenured Professor at the Medical College of Georgia, Augusta, USA. Dr. Raju was born in India and received his PhD from the All India Institute of Medical Sciences, a premier medical research institution in New Delhi. After his PhD work, he came to the University of Minnesota in 1992. He later joined the laboratory of Dr. Chella David at the Mayo Clinic to further his postdoctoral training in immunogenetics. He was later recruited to the NIH in 2001 as a Senior Staff Fellow. In 2007, he moved to the University of Alabama at Birmingham as an Associate Professor, where he began his investigations in trauma immunobiology and the influence of aging. In 2013, he came to Augusta University, as a Full Professor, where he was the founding director of the PhD program in Applied Health Sciences. In 2024 Dr. Raju received the Distinguished Basic Science Research Faculty Award. Dr. Raju's research has been continuously funded by the NIH and is currently funded by grants from the NIH, the Department of Defense, and the Department of Veteran's Affairs. He reviewed grants for several agencies and served as a chartered member of an NIH study section. He has published over 90 articles, most as first or last author. He is on the editorial board of several peer-reviewed journals. Dr. Raju's current research interests include acute senescence in trauma and sepsis, senolytics as a therapeutic tool, and maturation-dependent factors affecting longevity.

REGINSTER Jean-Yves

Jean-Yves Reginster M.D., M.PH. Ph.D. is currently Emeritus Professor of Epidemiology, Public Health and Health Economics as well as Emeritus Professor of Bioethics and Societal Medicine at the University of Liège where he also serves as the Honorary Chair of the Bone and Cartilage Metabolism Unit. He was the Director of the Division of Public Health, Epidemiology and Health Economics at the University of Liège. He is Director of the WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Aging. He is Professor at the Protein research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia. He is an active researcher who has authored more than 1100 publications, mainly dedicated to the pathophysiology, epidemiology, health economics, clinical and translational aspects of osteoporosis, osteoarthritis, frailty and sarcopenia. Among his other professional activities, Professor Reginster is President of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Co-Founder and Board member of the International Osteoporosis Foundation (IOF), where he serves as Secretary General. He previously served as Adjunct Professor of Medicine at Georgetown University Medical Center, Washington DC, USA. He was the Belgian alternate member for the Efficacy Working Party at the Committee for Human Proprietary Medicines (CHMP) of the European Medicines Agency (EMA) where he acted as rapporteur/co-rapporteur for the guidelines for the registration of drugs to be used in the management of osteoporosis and osteoarthritis.

ROLLAND Yves

Yves Rolland (MD, PhD) is Professor of Internal Medicine and Geriatrics at the IHU HealtAge of Toulouse (France) and has a postgraduate diploma in sports medicine. He is member of the CERPOP Team, UMR1295 (INSERM) at the University Toulouse III Paul Sabatier (MAINTAIN - MAintain Functions and INTrinsec capacities with Aging: Preventive and Personalized INterventional Research). He is the author of more than 300 articles indexed Pubmed. In 2023, he published "Challenges in developing Geroscience trials" in Nature Com and "Current and investigational medications for the treatment of sarcopenia" in Metabolism.

RYAN Joanne

Dr. Ryan is an epidemiologist and Head of the Biological Neuropsychiatry and Dementia research unit in the School of Public Health and Preventive Medicines at Monash University Australia. (SPHPM, Monash University, Australia). She is co-Principal Investigator (PI) of the ASPREE-XT study of aging in a cohort of over 12,000 older Australian and US individuals who have been followed for more than 12 years, and PI of the STAREE-Mind randomized controlled trial investigating the effect of statins versus placebo on cognitive health in 10,000 older Australians over 5 years. She has over 260 publications including in leading journals such as New England Journal of Medicine, Neurology, Alzheimer's and Dementia, Journal of Geriatrics, Nature Aging and Lancet series. The vast majority of her research is focused on preventative interventions and risk prediction for major geriatric conditions, and the identification of blood biomarkers. In ASPREE, Dr. Ryan has led the development and validation of

a deficit accumulation frailty index, and identified sex-specific associations between DNA methylation clocks of biological aging and both frailty and cognitive aging.



SIERRA Felipe

Felipe Sierra, Ph.D. is the Chief Scientific Officer at Hevolution Foundation, a non-profit organization headquartered in Riyadh, Saudi Arabia, that awards grants and early-stage investments to support research in the fields of healthy longevity and geroscience. Trained as a biochemist in his native Chile, he obtained a PhD in Biochemistry and Molecular Biology from the University of Florida in 1983 and has since then worked in Academia, Industry and Government, in a career that spans South America (Chile), USA and Europe (Switzerland and France). Dr. Sierra served as Director of the Division of Aging Biology, NIA/NIH from April 2006 to March 2020. During his tenure at the NIH, he developed the concept of Geroscience and created the trans-NIH Geroscience Interest Group (GSIG), to promote research on the "geroscience hypothesis" which states that slowing the rate of aging will delay the initiation or diminish the severity of adult-onset diseases and loss-of-resilience. He has received multiple recognitions, including thrice the NIH Director's Awards, a BEACON Award and a Career Achievement Award from the American Aging Association. After his tenure at NIH he went on to work as Director of Geroscience for the Inspire program in Toulouse, France, and most recently, as Chief Scientific Officer at Hevolution Foundation.

SLAWIN Kevin

Kevin Slawin, M.D. is the Founder and CEO of Eos SENOLYTIX (https://eossenolytix.com), a longevity company whose lead program is focused on proprietary senolytic peptides, that may restore the youthful balance of aged or "senescent" and young cells throughout the organs of the body. He is also the Founder and CEO of Phoenix SENOLYTIX (https://phoenixsenolytix.com), a longevity company developing novel gene therapies targeting senescent cells, among other fundamental mechanisms of aging. He was the co-founder of Bellicum Pharmaceuticals, Inc., leading Bellicum to a successful $161 million IPO in December 2014. He is also Founder, Chairman and CEO of PrintBio, Inc. (https://printbio.com), the only clinical- and commercial-stage regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants. He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos (https://miamimedicos.com), a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.

STUBBS Brianna

Dr. Stubbs is the Lead Translational Scientist at The Buck Institute for Research on Aging, where her work focusses on development of exogenous ketones for consumer and therapeutic products and on researching ketone esters for healthy aging. She is a world expert in exogenous ketone metabolism and its implications for performance, resilience and health-span. She completed her PhD in Metabolic Physiology at the University of Oxford, studying metabolism and translational application of exogenous ketones. Whilst completing her studies she was a two-time World Champion in lightweight rowing on Team Great Britain. Brianna spent two years as Research Lead at a San Francisco start-up, where she launched the world's first ketone ester consumer product and received $6M of funding from the US Special Operations Command to investigate exogenous ketone impacts on performance in extreme environments. Since moving to The Buck, she received the inaugural NIA Research and Entrepreneurial Development Immersion K01 award, and in partnership with Juvenescence, launched a second consumer product and co-founded a ketone- therapeutic company. Along with her mentor, Dr John Newman, in 2023 she established the Buck Institute Clinical Research Unit.

TAGLIAFICO Luca

Dr. Luca Tagliafico graduated in medicine from the University of Genoa (Italy) with a Neuroimmunology diploma supplement in 2017. After graduation he worked as a research fellow at the Parkinson's Center of San Martino Hospital in Genoa. Subsequently, he completed a residency in Geriatrics at the University of Genoa in 2022, during which he was actively engaged in clinical research, especially regarding the application of nutritional interventions in pathologies like Alzheimer's disease and to improve immunosenescence in vulnerable patients. He also visited the Alzheimer's Unit at Fatebenefratelli Hospital in Brescia (Italy) in this context. Currently, he is a PhD candidate in Hemato-Oncology and Clinical-Translational Internal Medicine at the University of Genoa. In 2022 and 2023, during his PhD, he visited in the USA the Alzheimer's Center at Temple University and the Mitochondrial Cell Biology Lab at Rutgers University, where he conducted a study on fasting and inorganic polyphosphate interactions in neurons. At the Biogerontology Laboratory at the University of Genoa, he continues to assess these interactions within various tumor lines and the role of inorganic polyphosphate in cellular senescence together with clinical research. Dr. Tagliafico has a profound interest in age-related diseases, metabolism, healthy aging, and translational geroscience.

TOUCHON Jacques

Jacques Touchon, MD, PhD is Emeritus Professor at Montpellier University France , member of the neurology and brain aging INSERM UNIT 1061. He is the Editor in Chief of the Journal of Prevention of Alzheimer's disease (JPAD), co-Chairman and founding member of the of the Clinical Trials on Alzheimer's Disease conference (CtaD). Jacques Touchon obtained his MD in 1979, and from 1980 to 1984 degrees in neurology, psychiatry, neurophysiology and geriatric. Formerly, Jacques Touchon was Professor of Neurology at the Montpellier Medical School (1990-2014) Chief of the Neurology Department of the Montpellier University Hospital (2004-2014), Dean of the Montpellier Medical School (2000-2010), Director of the Center for Memory Resources and Research (CMRR) for the Languedoc-Roussillon region (2004-2014). His areas of interest are Alzheimer's Disease, affections of the central nervous system, aging and neurodegenerative diseases. He was awarded for excellence in Alzheimer Disease Research: Academic Palms in 1999, PINEL prize in 2000 and in 2007 Chevalier de la Légion d'Honneur.

VELLAS Bruno

Bruno Vellas, MD, PhD – Bruno Vellas is the President Founder of the Institut Hospitalier Universitaire (IHU) HealthAge in healthy aging, prevention and Geroscience in Toulouse (France) at the Toulouse University Hospital and is member of INSERM UMR 1295. His main interests are: clinical trials in Alzheimer's disease and Geroscience, which have been supported by several national, European and international research grants. He is the author and co-author of more than 700 publications in peer-review journals, Index H over 140. He is invited professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM (USA) and part of the new NIH funded Alzheimer research and clinical center in Albuquerque. He is a member of the Scientific Advisory Board of several major scientific institutions in France, EU, China, Japan and the US. Since 2016, he is titular member of the French National Academy of Medicine, Officier de la Légion d'Honneur. He is the past president of the IAGG (International Association of Gerontology and Geriatrics), a NGO with a seat at the United Nations. Since September 2017, he is the chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training and Coordinator of the INSPIRE program in the field of Geroscience.

WEBSTER Micah

Micah Webster currently serves as the Senior Director, Translational Sciences and leads Discovery Biology and Biomarker Development Programs at Epirium Bio. He joined Epirium as Director, Translational Sciences in September 2023, bringing over 7 years of experience in biotech drug discovery and development. Prior to joining Epirium, Micah was Associate Director, Translational Sciences at Scholar Rock where he supported Discovery Biology programs for myostatin inhibitors in neuromuscular and metabolic disease as well as new target validation in fibrosis. While at Scholar Rock, he led clinical biomarker strategy and contributed to preclinical development of apitegromab. Prior to starting a career in biotech, Micah received the Ruth L. Kirschstein National Research Service Award from the National Institutes of Health for his postdoctoral research fellowship on skeletal muscle stem cells and muscle regeneration in the lab of Chen-Ming Fan, Ph.D., at the Carnegie Institution for Science. Micah received a Ph.D. in cellular and molecular biology from Johns Hopkins University.